Breast Cancer - High Risk Panel
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000505666.21
- Last updated: 2022-07-18
- Test version history
- 505666.22, last updated: 2022-07-22
- 505666.21, last updated: 2022-07-18
- 505666.20, last updated: 2018-07-19
- 505666.19, last updated: 2018-07-03
- 505666.18, last updated: 2018-02-23
- 505666.17, last updated: 2018-02-05
- 505666.16, last updated: 2018-01-15
- 505666.15, last updated: 2017-12-04
- 505666.14, last updated: 2017-02-07
- 505666.13, last updated: 2017-01-11
- 505666.12, last updated: 2017-01-06
- 505666.11, last updated: 2017-01-03
- 505666.10, last updated: 2016-09-26
- 505666.9, last updated: 2016-07-08
- 505666.8, last updated: 2016-03-30
- 505666.7, last updated: 2016-03-08
- 505666.6, last updated: 2016-01-28
- 505666.5, last updated: 2015-08-14
- 505666.4, last updated: 2015-05-19
- 505666.3, last updated: 2015-05-14
- 505666.2, last updated: 2015-02-27
- 505666.1, last updated: 2014-06-06
Clinical testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Familial cancer of breast
Offered by PreventionGenetics
Overview
Test name
HelpThe name the laboratory assigns the test. Used as the default title of the page specific to the test.Breast Cancer - High Risk Panel
This is a clinical test intended for HelpPurposes or indications for the test. Lab-provided.: Diagnosis, Mutation Confirmation, Pre-symptomatic, Risk Assessment, Screening
Click Indication tab for more information.
Please visit Lab website for details. Additional specimen types may be acceptable based on method. Please contact us about prenatal cases.
Order URL HelpLink to the laboratory webpage with information about how to order this test. Please note that clicking on this link will open a new tab in your internet browser.: https://www.preventiongenetics.com/forms.php
Specimen source
Methodology
HelpThe assay's major method category (biochemical, cytogenetic or molecular genetics); method category (i.e. enzyme assay, chromosome breakage studies, targeted mutation analysis); methodology (i.e. the name of the method used) and instruments used when performing this test.- Molecular Genetics
- DDeletion/duplication analysis
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
- Other
- CSequence analysis of the entire coding region
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
- Other
- TTargeted variant analysis
- Bi-directional Sanger Sequence Analysis
- Applied Biosystems 3730 capillary sequencing instrument
Not provided
Clinical validity
HelpHow consistently and accurately the test detects or predicts the intermediate or final outcomes of interest. Lab-provided.Not provided
Test services
HelpLaboratory's order or catalog code for the test (used in the order requisition form).- Clinical Testing/Confirmation of Mutations Identified Previously, Order code: 5431
- Custom Deletion/Duplication Testing, Order code: 5431
- Custom Sequence Analysis, Order code: 100, 200, 300
- Maternal cell contamination study (MCC), Order code: 800
- Custom Prenatal Testing, Order code: 990
- USPSTF, 2019Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force
- USPSTF, 2013Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation (See 2019 Update)
- NCI PDQ, Breast and Gynecologic CancersGenetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version
- NCI PDQ, Cancer Genetics CounselingCancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Version
- NICE, 2024UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024
- NICE, 2023UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023
- NCCN, 2023Breast Cancer, NCCN Guidelines Version 4.2022
- NCCN, 2022NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022
- ACMG ACT, 2019American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019
- OMIM
- View AKT1 variations in ClinVar
- View ATM variations in ClinVar
- View BARD1 variations in ClinVar
- View BRCA1 variations in ClinVar
- View BRCA2 variations in ClinVar
- View CASP8 variations in ClinVar
- View CDH1 variations in ClinVar
- View ESR1 variations in ClinVar
- View HMMR variations in ClinVar
- View KRAS variations in ClinVar
- View NQO2 variations in ClinVar
- View SLC22A18 variations in ClinVar
- View PHB1 variations in ClinVar
- View PIK3CA variations in ClinVar
- View RAD51 variations in ClinVar
- View TP53 variations in ClinVar
- View XRCC3 variations in ClinVar
- View RAD54L variations in ClinVar
- View PPM1D variations in ClinVar
- View RB1CC1 variations in ClinVar
- View BRIP1 variations in ClinVar
- RefSeqGene
- Coriell Institute for Medical Research
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.